Want to see HK:1228 full AI Analyst Report?
Top Page
CANbridge Pharmaceuticals Inc.
(1228)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$2.00
▼(-20.63% Downside)
Action:Reiterated
Date:10/01/26
The score is primarily held back by weak financial performance—negative equity, persistent operating losses, and ongoing negative free cash flow. Technicals are a notable offset with the stock trading above key moving averages and showing moderately positive momentum, while valuation remains constrained by a negative P/E and lack of dividend support.
Positive Factors
Rare-Disease Focus
A focused rare-disease strategy can support specialized expertise in licensing, regulatory execution, patient access, and commercialization. Concentrating on orphan-drug markets may help the company build differentiated capabilities and serve areas that are less suited to broad-based pharmaceutical competitors over the medium term.
Negative Factors
Negative Equity
Persistently negative shareholders’ equity signals a fragile capital structure and limits the company’s financial flexibility. It can make future financing more difficult or dilutive, complicate leverage assessment, and leave fewer balance-sheet resources available to absorb setbacks in development or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Rare-Disease Focus
A focused rare-disease strategy can support specialized expertise in licensing, regulatory execution, patient access, and commercialization. Concentrating on orphan-drug markets may help the company build differentiated capabilities and serve areas that are less suited to broad-based pharmaceutical competitors over the medium term.
Read all positive factors
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.06B
Dividend YieldN/A
Average Volume (3M)697.50K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-8.00%
EPS Growth51.26%
CountryHK
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding597,723,300
10 Day Avg. Volume563,700
30 Day Avg. Volume697,505
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)-3.07
Price to Sales (P/S)21.02
P/FCF Ratio-27.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
Company Description
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzym...
How the Company Makes Money
CANbridge generally makes money through the development and commercialization of rare-disease drug assets in its target geographies. Key revenue streams typically include: (1) Product sales: revenue from selling approved therapies through specialt...
CANbridge Pharmaceuticals Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.67M | 49.98M | 85.10M | 102.87M | 78.97M | 31.16M |
| Gross Profit | 39.79M | 36.55M | 54.30M | 64.16M | 48.89M | 18.78M |
| EBITDA | -87.79M | -80.55M | -313.26M | -341.43M | -454.63M | -1.06B |
| Net Income | -81.51M | 14.82M | -442.62M | -378.84M | -483.48M | -1.08B |
Balance Sheet | ||||||
| Total Assets | 192.38M | 165.46M | 116.81M | 395.36M | 702.04M | 892.52M |
| Cash, Cash Equivalents and Short-Term Investments | 88.10M | 66.65M | 10.50M | 137.49M | 451.16M | 745.82M |
| Total Debt | 28.81M | 16.09M | 135.78M | 141.93M | 155.28M | 52.10M |
| Total Liabilities | 388.31M | 507.36M | 591.30M | 435.15M | 393.49M | 199.13M |
| Stockholders Equity | -195.93M | -341.90M | -474.49M | -39.79M | 308.56M | 693.39M |
Cash Flow | ||||||
| Free Cash Flow | -112.02M | -38.22M | -122.50M | -319.09M | -315.76M | -592.40M |
| Operating Cash Flow | -111.98M | -38.21M | -122.39M | -278.23M | -280.98M | -587.07M |
| Investing Cash Flow | 176.00K | 1.23M | 13.93M | -26.86M | -34.79M | 126.09M |
| Financing Cash Flow | 93.14M | 92.47M | -18.57M | -28.02M | -20.70M | 854.31M |
CANbridge Pharmaceuticals Inc. Technical Analysis
Negative
2.52
Price Trends
1.92
Negative
1.98
Negative
2.23
Negative
Market Momentum
-0.04
Positive
39.01
Neutral
17.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Negative. The current price of 2.52 is above the 20-day moving average (MA) of 1.89, above the 50-day MA of 1.92, and above the 200-day MA of 2.23, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.01 is Neutral, neither overbought nor oversold. The STOCH value of 17.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1228.
CANbridge Pharmaceuticals Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
52 Neutral | HK$3.62B | 6.01 | 47.76% | ― | 286.20% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.06B | -9.52 | 30.32% | ― | -8.00% | 51.26% | |
48 Neutral | HK$6.32B | -56.20 | -9.45% | ― | 68.12% | 81.84% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:1228
CANbridge Pharmaceuticals Inc.
1.77
-0.21
-10.61%
HK:9966
Alphamab Oncology
6.22
-5.47
-46.79%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.60
-2.66
-36.64%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:2171
CARsgen Therapeutics Holdings Ltd.
10.63
-6.92
-39.43%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge boosts rare disease footprint after HK$200 million WuXi stake
Aug 28, 2026
CANbridge Pharmaceuticals reported interim results marked by a strategic HK$200 million investment from WuXi Biologics HealthCare Venture, which acquired a 16.27% stake and became the company’s second-largest shareholder. The proceeds are ea...
CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli
Aug 17, 2026
CANbridge Pharmaceuticals Inc. announced that its rare disease drug Livmarli has received reimbursement approval from Taiwan’s National Health Insurance Administration. The coverage, effective September 1, 2026, applies to patients with Alag...
CANbridge sets August board meeting to approve 2026 interim results
Aug 17, 2026
CANbridge Pharmaceuticals Inc. has scheduled a board meeting for August 28, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The meeting will also authorize publication of these interim figures, a ro...
CANbridge Pharmaceuticals Refreshes Board and Committee Leadership With New Independent Director
Aug 5, 2026
CANbridge Pharmaceuticals Inc., a Hong Kong-listed biopharmaceutical company, has announced changes to its board and committee leadership. The firm relies on independent non-executive directors to oversee remuneration and audit functions, reflecti...
CANbridge Pharmaceuticals Details Board and Committee Structure
Aug 5, 2026
CANbridge Pharmaceuticals has outlined the composition of its board of directors, naming Chairman and Chief Executive Officer Dr. James Qun Xue as the sole executive director alongside two non-executive directors and four independent non-executive...
CANbridge Shareholders Unanimously Approve WuXi Biologics Service Agreement
Aug 3, 2026
CANbridge Pharmaceuticals shareholders have approved, by poll, an ordinary resolution endorsing the WuXi Biologics Service Procurement Framework Agreement at an extraordinary general meeting held on August 3, 2026. Under the approved framework, di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.